Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376896 · ClinicalTrials.gov registry record · Phase 1
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00376896 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 25 participants.
The verdict
NCT00376896, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a three-period crossover study to compare GW876008 and placebo to see if GW876008 will normalise blood flow responses after different emotional stimuli.
Interventions
- OTHER Placebo
- DRUG GW876008 200mcg
- DRUG GW876008 20mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376896
The ClinicalTrials.gov registry entry for NCT00376896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00376896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376896 about?
NCT00376896 is a clinical study titled "Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers". This is a three-period crossover study to compare GW876008 and placebo to see if GW876008 will normalise blood flow responses after different emotional stimuli.
What is the current status of trial NCT00376896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00376896?
The interventions under investigation include: Placebo (OTHER), GW876008 200mcg (DRUG), GW876008 20mcg (DRUG).
Who is sponsoring clinical trial NCT00376896?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.